IP Library › Granted Patent US 12,637,506
Granted Patent B2
US 12,637,506 · App. 17/825,314 · Granted May 26, 2026

Fc-receptor binding modified asymmetric antibodies and methods of use

Inventors: Joerg Thomas Regula (Munich, DE); Wolfgang Schaefer (Mannheim, DE); Tilman Schlothauer (Penzberg, DE)
C07K16/22C07K16/00C07K16/2863C07K16/468A61K2039/505A61K2039/54C07K2317/31C07K2317/33C07K2317/35C07K2317/41C07K2317/52C07K2317/56C07K2317/565C07K2317/71C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,637,506
App. No.
17/825,314
Granted
May 26, 2026
Kind
B2
Abstract

Herein is reported an IgG class Fc-region comprising a first variant Fc-region polypeptide and a second variant Fc-region polypeptide, wherein the first variant Fc-region polypeptide is derived from a first parent IgG class Fc-region polypeptide and the second variant Fc-region polypeptide is derived from a second parent IgG class Fc-region polypeptide, whereby the first parent IgG class Fc-region polypeptide is identical to or different from the second parent IgG class Fc-region polypeptide, and the first variant Fc-region polypeptide differs from the second variant Fc-region polypeptide in one or more amino acid residues other than those amino acid residues in which the first parent IgG class Fc-region polypeptide differs from the second parent IgG class Fc-region polypeptide, and the IgG class Fc-region comprising the first variant Fc-region polypeptide and the second variant Fc-region polypeptide has an affinity to a human Fc-receptor that is different than that of an IgG class Fc-region comprising the first parent IgG class Fc-region polypeptide of a) and the second parent IgG class Fc-region polypeptide of a).

Claims (18)

1 . An IgG class Fc-region comprising a first variant Fc-region polypeptide and a second variant Fc-region polypeptide, wherein:

a) the first variant Fc-region polypeptide is derived from a first parent IgG class Fc-region polypeptide and the second variant Fc-region polypeptide is derived from a second parent IgG class Fc-region polypeptide, whereby the first parent IgG class Fc-region polypeptide is identical to or different from the second parent IgG class Fc-region polypeptide;

b) the first variant Fc-region polypeptide differs from the second variant Fc-region polypeptide in one or more amino acid residues other than those amino acid residues in which the first parent IgG class Fc-region polypeptide differs from the second parent IgG class Fc-region polypeptide; and

c) the IgG class Fc-region comprising the first variant Fc-region polypeptide and the second variant Fc-region polypeptide has an affinity to a human Fc-receptor that is different than that of an IgG class Fc-region comprising the first parent IgG class Fc-region polypeptide of a) and the second parent IgG class Fc-region polypeptide of a),

wherein:

the human Fc-receptor is the human neonatal Fc-receptor;

the first and the second Fc-region polypeptide are both of human IgG1 of SEQ ID NO: 60 and have the following mutations (numbering according to Kabat EU index numbering system): H433A in the first variant Fc-region polypeptide, and H310A and Y436A in the second variant Fc-region polypeptide, or H433A and H310A in the first variant Fc-region polypeptide, and Y436A in the second variant Fc-region polypeptide, or H433A and Y436A in the first variant Fc-region polypeptide, and H310A in the second variant Fc-region polypeptide;

the IgG1 Fc-region has a reduced binding to Staphylococcus protein A than an IgG1 Fc-region comprising the first IgG1 Fc-region polypeptide of a) and the second IgG1 Fc-region polypeptide of a); and

wherein:

i) the first IgG1 Fc-region polypeptide and the second IgG1 Fc-region polypeptide have no mutations other than those stated above, or

ii) the first IgG1 Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A and the second IgG1 Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A, or

iii) the first IgG1 Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, 1235A, P329G and the second IgG1 Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A, P329G, or

iv) the first IgG1 Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A, S354C, T366W and the second IgG1 FC-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A, Y349C, T366S, L368A, Y407V, or

v) the first IgG1 Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A, P329G, S354C, T366W and the second IgG1 Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A, P329G, Y349C, T366S, L368A, Y407V, or

vi) the first IgG1 Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutation K392D and the second IgG1 Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations D399K, D356K, and/or E357K.

2 . The IgG class Fc-region according to claim 1 , wherein the human Fc-receptor is the human neonatal Fc receptor (FcRn) or the human Fcgamma III receptor (FcγRIII).

3 . The IgG class Fc-region according to claim 2 , wherein the human Fc-receptor is the human neonatal Fc-receptor.

4 . The IgG class Fc-region according to claim 1 , wherein the affinity to a human Fc-receptor is increased or reduced by 10% or more determined by surface plasmon resonance (SPR).

Priority Claims (2)
EP 13165725 · Apr 29, 2013 · regional
EP 14151314 · Jan 15, 2014 · regional
Continuity (3)
Continuation 16422147 · May 24, 2019
Continuation 14785900
Related Publication 20220324955A1 · Oct 13, 2022
References Cited (63)
US 6737056B1 · Presta · 2004 [cited by applicant]
US 7923538B2 · Shitara et al. · 2011 [cited by applicant]
US 7951917B1 · Arathoon · 2011 [cited by examiner]
US 8703132B2 · Imhof-Jung · 2014 [cited by examiner]
US 9217880B2 · Pugh et al. · 2015 [cited by applicant]
US 9266967B2 · Klein · 2016 [cited by examiner]
US 10195262B2 · Wacker et al. · 2019 [cited by applicant]
US 10316092B2 · Yao et al. · 2019 [cited by applicant]
US 11091541B2 · Hartmann · 2021 [cited by examiner]
US 12264196B2 · Regula · 2025 [cited by examiner]
US 20160231320A1 · Young et al. · 2016 [cited by applicant]
BR 102016022721A2 · 2018 [cited by applicant]
CA 3159061A1 · 2013 [cited by applicant]
EP 1601697B1 · 2007 [cited by applicant]
WO 9734631A1 · 1997 [cited by applicant]
WO 2005077981A2 · 2005 [cited by applicant]
WO 2006053301A2 · 2006 [cited by applicant]
WO WO2011008517A2 · 2011 [cited by applicant]
WO WO2011131746A2 · 2011 [cited by examiner]
WO 2012069557A1 · 2012 [cited by applicant]
WO 2012093125A1 · 2012 [cited by applicant]
WO WO2012125850A1 · 2012 [cited by examiner]
WO 2013056233A1 · 2013 [cited by applicant]
WO 2013063702A1 · 2013 [cited by applicant]
WO 2013166594A1 · 2013 [cited by applicant]
WO 2015057668A1 · 2015 [cited by applicant]
The English translation of the Decision to Grant dated Jul. 26, 2022, in the related Russian Patent Application No. 2020122367/10(038452). [cited by applicant]
The Chinese Office Action, mailed on Feb. 27, 2023, in the related Chinese Patent Appl. No. 201911344011.0. [cited by applicant]
The English translation of the Chinese Office Action, mailed on Nov. 25, 2022, in the related Chinese Patent Appl. No. 201911266804.5. [cited by applicant]
The US Office Action, mailed on Dec. 30, 2022, in the related U.S. Appl. No. 16/590,938. [cited by applicant]
The US Office Action, mailed on Jan. 12, 2023, in the related U.S. Appl. No. 15/947,377. [cited by applicant]
DeLano et al., “Convergent Solutions to Binding at a Protein-Protein Interface,” Science, 287:1279-1283, Feb. 18, 2000. [cited by applicant]
Jansson et al., “All individual domains of [cited by applicant]
The English translation of the Japanese Office Action, mailed on May 16, 2022, in the related Japanese Patent Application No. 2021-092002. [cited by applicant]
The US Office Actions, mailed on Feb. 1, May 5, and May 20, 2022, in the related U.S. Appl. No. 16/590,938. [cited by applicant]
The US Office Action, mailed on Feb. 24, 2022, in the related U.S. Appl. No. 15/947,424. [cited by applicant]
Spiekermann et al., “Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life: Functional Expression of FcRn in the Mammalian Lung,” J Exp Med (2002) 196 (3): 303-310. [cited by applicant]
The Canadian Office Action, mailed on Feb. 17, 2022, in the related Canadian Patent Appl. No. 2,904,805. [cited by applicant]
The US Office Action, mailed on Aug. 30, 2021, in the related U.S. Appl. No. 15/947,377. [cited by applicant]
The English translation of the Chinese Office Action, mailed on Jul. 8, 2023, in the related Chinese Patent Appl. No. 201480024044.6. [cited by applicant]
The US Office Action, mailed on Jul. 5, 2023, in the related U.S. Appl. No. 16/590,938. [cited by applicant]
The US Office Action, mailed on Aug. 31, 2023, in the related U.S. Appl. No. 17/373,062. [cited by applicant]
The US Office Action, mailed on Sep. 23, 2024, in the related U.S. Appl. No. 15/947,424. [cited by applicant]
The US Office Action, mailed on Jan. 16, 2025, in the related U.S. Appl. No. 17/373,062. [cited by applicant]
The US Office Action, mailed on Oct. 23, 2024, in the related U.S. Appl. No. 18/079,307. [cited by applicant]
Tustian et al., “Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity,” MAbs May-Jun. 2016;8(4):828-38. [cited by applicant]
The English translation of the Japanese Office Action, mailed on Aug. 29, 2023, in the related Japanese Patent Appl. No. 2022-010878. [cited by applicant]
The English translation (Google Translate) of the Argentina Office Action, mailed on Dec. 22, 2023, in related Argentina Application No. 20140101718. [cited by applicant]
US Office Action, mailed on Feb. 16, 2024, in related U.S. Appl. No. 16/590,938. [cited by applicant]
The English translation of the Reexamination Notification, mailed on Apr. 17, 2025, in the related Chinese Appl. No. 201480023252.4. [cited by applicant]
The Third Party Observations, posted on Dec. 1, 2023, in the related European Patent Appl. No. 15700545.5. [cited by applicant]
The English translation of the Chinese Office Action, mailed on Aug. 28, 2023, in the related Chinese Patent Appl. No. 202110445639.0. [cited by applicant]
The US Office Action, mailed on Sep. 22, 2023, in the related U.S. Appl. No. 15/947,424. [cited by applicant]
The English translation of the Chinese Office Action, mailed on Jan. 24, 2024, in the related Chinese Patent Appl. No. 202110445639.0. [cited by applicant]
US Office Action, mailed on Mar. 13, 2024, in related U.S. Appl. No. 17/373,062. [cited by applicant]
The International Search Report and Written Opinion, mailed on Apr. 28, 2015, in related International Patent application No. PCT/EP2015/050425. [cited by applicant]
Hober et al., Protein A chromatography for antibody purification J Chrom B 848:40-47 (2007). [cited by applicant]
Huber et al., “Crystallization and stoichiometry of binding of a complex between a rat intestinal: Fc receptor and Fc,” J Mol Biol 230:1077-1083 (1993). [cited by applicant]
Kim et al., “FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye,” Molec Vision 15:2803-2812 (Dec. 16, 2009). [cited by applicant]
Kim et al., “Identifying amino acid residues that influence plasma clearance of marine IgG1 fragments by site-directed mutagenesis” Eur J Immunol 24(3):542-548 (Mar. 1994). [cited by applicant]
Kim et al., Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn Eur Immunol 29(9):2819-2825 (Sep. 1999). [cited by applicant]
Kuo et al., “Neonatal Fc receptor: from immunity to therapeutics” J Clin Immunol 30:777-789 (2010). [cited by applicant]
Qiao et al., Dependence of antibody-mediated presentation of antigen on FcRn PNAS 105(27):9337-9342 (2008). [cited by applicant]